This will involve submitting a request to your insurance company explaining why the medication is medically necessary
A 2024 systematic review and meta-analysis across 22 randomized controlled trials found that lean body mass (primarily muscle) accounts for roughly 25% of total weight lost on GLP-1 receptor agonists, with some individual trials reporting higher proportions
The FDA has described categories for bulk substances used in compounding and has highlighted safety concerns for certain substances
Development of Glucagon-Like Peptide 1 Receptor Agonists for the Management of Obesity Glucagon-like peptide 1 receptor agonists (GLP-1RAs), including liraglutide and semaglutide, were initially developed for the treatment of type 2 diabetes but were found to be effective not only in reducing blood glucose levels but body weight as well [18,19,20]
PMID: 36038016
Other randomized control trials show similar results, too, with the best results coming from supervised exercise exceeding the 150-minute/week guideline